Figure 2. Diastolic (A–C) and (D) systolic function 2 weeks (top row) and 4 weeks (bottom row) after TAC/DOCA surgery: Echocardiography.

Top. Mice have diastolic dysfunction 2 weeks after TAC/DOCA surgery. cRbm20^ΔRRM TAC/DOCA mice were studied that had received 1 week post-surgery DMSO (control) or raloxifene (note that the one week period from start of injection to echo analysis is insufficient for N2BAsc expression). Both TAC/DOCA groups had a reduced mitral E deceleration time (A), increased mitral E/e’ ratio (B) and increased E/A ratio (C), all indicating diastolic dysfunction. The ejections fraction (D) is normal. Bottom. Recovery of diastolic dysfunction in cRbm20^ΔRRM-raloxifene mice 4 weeks after TAC/DOCA surgery. (Note that the 3 week period from start of raloxifene injection to echo analysis results in an optimal N2BAsc expression level in cRbm20^ΔRRM-raloxifene mice.) The cRbm20^ΔRRM-DMSO group had (compared to sham) a reduced mitral E deceleration time, increased mitral E/e’ ratio and increase E/A ratio, all of which indicate diastolic dysfunction. The cRbm20^ΔRRM-raloxifene group had normalized diastolic parameters. The ejection fraction was normal in both TAC/DOCA groups. * p≤0.05; **p≤0.01, ***p≤0.001; ****p≤0.0001. (n=20 sham, 29 cRbm20^ΔRRM-DMSO, and 37 cRbm20^ΔRRM-raloxifene mice.)